Xtant Medical Q2 revenue up 48% to $29.9M; posts positive Adjusted EBITDA of $0.5M

Xtant Medical Holdings, Inc.

2024-Q2 EPS reported -$0.06 revenue$57,816,000

Revenue $29.9M, +48% YoY; gross margin 62.1% (+50 bps); net loss $3.9M ($0.03/sh) vs $2.2M loss year ago.
Fifth consecutive quarter of positive Adjusted EBITDA: $0.5M vs $0.1M in prior year quarter.
Launched SimpliGraft and SimpliMax amniotic membrane allografts; added 15 new distributors and 20 IDN contracts in Q2.
Entered $5.0M private placement at $0.64/share on August 7, 2024; cash $5.4M at June 30, 2024.
Reaffirms FY2024 revenue guidance $116M-$120M (27%-31% annual growth).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.